Patents by Inventor David Paschon

David Paschon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions for linking DNA-binding domains and cleavage domains
    Patent number: 11920169
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases with alternative configurations. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: March 5, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • METHODS AND COMPOSITIONS FOR TREATMENT OF A GENETIC CONDITION
    Publication number: 20230416775
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Application
    Filed: November 7, 2022
    Publication date: December 28, 2023
    Inventors: Gregory J. Cost, Dmitry Guschin, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES
    Publication number: 20230346844
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Application
    Filed: September 12, 2022
    Publication date: November 2, 2023
    Inventors: Maria Chiara Bonini, Pietro Genovese, Philip D. Gregory, Michael C. Holmes, Luigi Naldini, David Paschon, Elena Provasi, Lei Zhang
  • TARGETED DISRUPTION OF T CELL AND/OR HLA RECEPTORS
    Publication number: 20230295563
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Application
    Filed: October 21, 2022
    Publication date: September 21, 2023
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang
  • DNA-binding proteins and uses thereof
    Patent number: 11661612
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: May 30, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Targeted integration into the PPP1R12C locus
    Patent number: 11649468
    Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 16, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Russell DeKeiver, Philip D. Gregory, David Paschon, Phillip Tam, Fyodor Urnov
  • Methods and compositions for treating hemophilia
    Patent number: 11634463
    Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins involved in clotting into the genome of a cell for treating conditions including hemophilias.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: April 25, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • METHODS AND COMPOSITIONS FOR MODULATING PD1
    Publication number: 20220395556
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Application
    Filed: January 28, 2022
    Publication date: December 15, 2022
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • Targeted disruption of T cell and/or HLA receptors
    Patent number: 11512287
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 29, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang
  • DNA-BINDING PROTEINS AND USES THEREOF
    Publication number: 20220356493
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Application
    Filed: June 11, 2021
    Publication date: November 10, 2022
    Inventors: Philip D. GREGORY, Jeffrey C. MILLER, David PASCHON, Edward J. REBAR, Siyuan TAN, Fyodor URNOV, Lei ZHANG
  • Methods and compositions for treatment of a genetic condition
    Patent number: 11492643
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: November 8, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • TARGETED DISRUPTION OF THE T CELL RECEPTOR
    Publication number: 20220315932
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Application
    Filed: May 19, 2022
    Publication date: October 6, 2022
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
    Patent number: 11439666
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 13, 2022
    Assignees: Sangamo Therapeutics, Inc., Ospedale San Raffaele srl
    Inventors: Maria Chiara Bonini, Pietro Genovese, Philip D. Gregory, Michael C. Holmes, Luigi Naldini, David Paschon, Elena Provasi, Lei Zhang
  • TARGETED DISRUPTION OF THE MHC CELL RECEPTOR
    Publication number: 20220175839
    Abstract: Disclosed herein are methods and compositions for inactivating MHC genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Application
    Filed: February 23, 2022
    Publication date: June 9, 2022
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Targeted disruption of the T cell receptor
    Patent number: 11352631
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 7, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Targeted disruption of the MHC cell receptor
    Patent number: 11285175
    Abstract: Disclosed herein are methods and compositions for inactivating MEW genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 29, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • HTT REPRESSORS AND USES THEREOF
    Publication number: 20220064237
    Abstract: Disclosed herein are HTT repressors and methods and compositions for use of these HTT repressors. Disclosed herein are methods and compositions for diagnosing, preventing and/or treating Huntington's Disease. In particular, provided herein are methods and compositions for modifying (e.g., modulating expression of) an HD HTT allele so as to prevent or treat Huntington Disease, including mHTT repressors (that repress mHTT transcripts and thus also repress mHTT protein expression).
    Type: Application
    Filed: January 15, 2020
    Publication date: March 3, 2022
    Inventors: Galen Carey, Matthew Chiocco, Vivian Choi, Brian Felice, Steven Froelich, Debra Klatte, Jeffrey Miller, David Paschon, Edward Rebar, Bryan Zeitler, Lei Zhang, H. Steve Zhang
  • Methods and compositions for modulating PD1
    Patent number: 11235026
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 1, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • HTT REPRESSORS AND USES THEREOF
    Publication number: 20210369872
    Abstract: Disclosed herein are Htt repressors and methods and compositions for use of these Htt repressors.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 2, 2021
    Inventors: Steven Froelich, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Htt repressors and uses thereof
    Patent number: 11123443
    Abstract: Disclosed herein are Htt repressors and methods and compositions for use of these Htt repressors.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: September 21, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Steven Froelich, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang